DDInter927 DDInter649
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.
Enzalutamide {u} (Compound) resembles {v} (Compound) Nilutamide
Enzalutamide {u} (Compound) resembles {v} (Compound) Bicalutamide
Enzalutamide {u} (Compound) binds {v} (Gene) CYP3A4
Enzalutamide {u} (Compound) upregulates {v} (Gene) RPL39L
Enzalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Enzalutamide {u} (Compound) causes {v} (Side Effect) Musculoskeletal pain
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Enzalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Relugolix
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Teriflunomide
Enzalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Remdesivir
Enzalutamide (Compound) resembles Nilutamide (Compound)
Enzalutamide (Compound) resembles Bicalutamide (Compound)
Enzalutamide (Compound) binds CYP3A4 (Gene)
Enzalutamide (Compound) upregulates RPL39L (Gene)
Enzalutamide (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Enzalutamide (Compound) causes Musculoskeletal pain (Side Effect)
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir